Released Aug 6, 2020, before the open
10-Q filed Aug 6, 2020, 37 days after period end · 0001564590-20-037284
Q2 2020 · 10-Q
Revenue$73.14M$73.14M −36.9% vs Q2 2019−30.2% vs Q1 2020
Net Income-$18.42M-$18.42M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.96-$0.96 N/M vs Q2 2019N/M vs Q1 2020
Gross Profit$49,969,000−44.5%
Operating Income-$21,000,000N/M
Operating Cash Flowderived$17,630,000+87.9%
Free Cash Flowderived$13,355,000+201.4%
Margins · derived
Gross margin68.3%−9.4 pt vs Q2 2019
Operating margin-28.7%−29.1 pt vs Q2 2019
Net margin-25.2%−24.7 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $73.14M | $115.85M | $111.55M | $108.94M |
| Net Income | -$18.42M | -$547.00K | $925.00K | $3.85M |
| EPS Diluted | -$0.96 | -$0.03 | $0.05 | $0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR